Search results
Pfizer Quadruples Its Covid Shot Price — And Other Vaccine Stocks Rocket
Investor's Business Daily· 2 years agoModerna snagged an upgrade Friday on the likelihood it will follow in Pfizer's footsteps in hiking...
Why Moderna Stock Rallied Today
Motley Fool· 2 years agoShares of Moderna (NASDAQ: MRNA) jumped 8.4% on Friday after rival drugmaker Pfizer (NYSE: PFE) said it intends to drastically increase the price of its...
Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 Billion
Investor's Business Daily· 8 months agoModerna stock and BioNTech led a sell-off Monday among Covid vaccine makers after Pfizer slashed...
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions
Investor's Business Daily· 2 years agoThe Biden administration is planning to stop paying for Covid vaccines and treatments, shifting the...
Pfizer, Moderna Try To Squeeze Blood From A Stone. Why It Probably Won't Work.
Investor's Business Daily· 10 months agoThe biggest names in Covid are updating their vaccines for a fall campaign, but that might not be...
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
Zacks via Yahoo Finance· 8 months agoDespite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable...
Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?
Zacks via Yahoo Finance· 1 year agoMuch of the social and economic post-pandemic recovery is accredited to Covid-19 vaccine makers...
Moderna Comes Swinging For Pfizer, GSK In The Mega-Billions RSV Market
Investor's Business Daily· 1 year agoModerna stock rose Wednesday after the biotech said its experimental RSV vaccine proved nearly 84%...
Is Pfizer Stock a Buy Now?
Motley Fool· 2 years agoOver the past year, Pfizer (NYSE: PFE) has been one of the safer stocks to hold. The company has been acquiring businesses to get stronger and more...
Moderna Stock: Buy, Sell, or Hold in 2023?
Motley Fool· 2 years agoModerna (NASDAQ: MRNA) shares delivered top returns to investors in the earlier days of the pandemic. This year, though, the stock is heading for a 30%...
